相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018)
Helio S. Sader et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2020)
Biochemical Characterization of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases
Ruslan Tsivkovski et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Impact of Intrinsic Resistance Mechanisms on Potency of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases in Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii
Olga Lomovskaya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Spectrum of Beta-Lactamase Inhibition by the Cyclic Boronate QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases: Enhancement of Activity of Multiple Antibiotics against Isogenic Strains Expressing Single Beta-Lactamases
Olga Lomovskaya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
In Vitro Activity of the Ultrabroad-Spectrum-Beta-Lactamase Inhibitor QPX7728 against Carbapenem-Resistant Enterobacterales with Varying Intrinsic and Acquired Resistance Mechanisms
Kirk Nelson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases
Scott J. Hecker et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Antibiotic resistance in Pseudomonas aeruginosa and adaptation to complex dynamic environments
Lea M. Sommer et al.
MICROBIAL GENOMICS (2020)
In Vivo Activity of QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor, in Combination with Beta-Lactams against Carbapenem-Resistant Klebsiella pneumoniae
Mojgan Sabet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
In Vitro Activity of the Ultra-Broad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Meropenem against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii
Kirk Nelson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial
Astrid Perez et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Geographic and Temporal Patterns of Antimicrobial Resistance in Pseudomonas aeruginosa Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997-2016
Dee Shortridge et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections
Krisztina M. Papp-Wallace
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Is Meropenem as a Monotherapy Truly Incompetent for Meropenem-Nonsusceptible Bacterial Strains? A Pharmacokinetic/Pharmacodynamic Modeling With Monte Carlo Simulation
Xiangqing Song et al.
FRONTIERS IN MICROBIOLOGY (2019)
Epidemiology and Mechanisms of Resistance of Extensively Drug Resistant Gram-Negative Bacteria
Emily M. Eichenberger et al.
ANTIBIOTICS-BASEL (2019)
Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis
Michael D. Parkins et al.
CLINICAL MICROBIOLOGY REVIEWS (2018)
Interplay between MexAB-OprM and MexEF-OprN in clinical isolates of Pseudomonas aeruginosa
Gertrudis Horna et al.
SCIENTIFIC REPORTS (2018)
Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art
Alberto Enrico Maraolo et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2017)
Pseudomonas aeruginosa infections in chronic obstructive pulmonary disease: Role of long-term antibiotic treatment
G. G. U. Rohde et al.
INTERNIST (2017)
Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone
Carla Lopez-Causape et al.
SCIENTIFIC REPORTS (2017)
Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis
Robert Wilson et al.
RESPIRATORY MEDICINE (2016)
Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies
Mohamed E. El Zowalaty et al.
FUTURE MICROBIOLOGY (2015)
In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure
Mar Sole et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem
Elena Riera et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Pseudomonas aeruginosa: resistance to the max
Keith Poole
FRONTIERS IN MICROBIOLOGY (2011)
Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation
Lois S. Lee et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2010)
Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms
Philip D. Lister et al.
CLINICAL MICROBIOLOGY REVIEWS (2009)
Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates
J Quale et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem
JL Kuti et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
分享论文
